As the healthcare industry seeks various solutions to minimize its environmental impact, many big-name companies are stepping up with ambitious strategies to lead the way.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, ...

Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli Lilly told CNBC, "Lilly will continue to work with those in health care, government and the ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Reuters reports that online weight loss company Noom will sell low-dose versions of Novo Nordisk's Wegovy. Compounding pharmacies like Noom have struggled to figure out how to sell GLP-1 weight ...

In its first-quarter 2025 investor letter, ClearBridge Large Cap Value Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...